To this end, we used verteporfin, which blocks the association of YAP with TEAD and thereby disrupts YAP-related transcriptional activity, and saracatinib, which is an SRC kinase inhibitor that was recently reported to exert suppressive activities against YAP1 in NPC [38, 45]. Here, YAP1 is linked to nasopharyngeal carcinoma.